A Well-Balanced Pipeline
Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.
| Compound* | Clinical phase | Indication |
Therapeutic principle |
Mode of action |
|---|---|---|---|---|
| Empagliflozin | Phase III |
Diabetes mellitus
|
SGLT-2-antagonist | Inhibition of glucose transporter-2 |
| BI 201335 | Phase III | Hepatitis C | Direct acting antiviral small molecule | Oral HCV NS3/4A protease inhibitor |
| Afatinib | Phase III | Non-small cell lung cancer (NSCLC) | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
| Afatinib | Phase III | Breast cancer | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
| Afatinib | Phase III |
Head and neck cancer |
Signal transduction inhibition | Novel irreversible ErbB Family blocker |
| Nintedanib | Phase III | Non-small cell lung cancer (NSCLC) | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
| Nintedanib | Phase III | Ovarian cancer | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
| Nintedanib | Phase III | Idiopathic pulmonary fibrosis (IPF) | Anti-fibrotic kinase inhibition | Anti-fibrotic kinase inhibitor |
| Olodaterol | Phase III | Chronic obstructive pulmonary Disease (COPD) | Long-acting beta-agonist | Bronchodilation |
| Tiotropium | Phase III | Asthma | Bronchodilatator | Long Acting Muscarinic Antagonist |
| BI 207127 | Phase II |
Hepatitis C |
Direct acting antiviral small molecule | Oral NS5B RNA-dependent polymerase inhibitor |
| Volasertib | Phase II | Various cancer types |
Cell-cycle kinase inhibition |
PLK-1 antagonist |
| New compound | Phase I | Various cancer types | Cell-cycle kinase inhibition | Mitotic checkpoint inhibitor |
| New compound | Phase I | Diabetes mellitus type II | 11ß-HSD-1-antagonist |
* These are investigational agents; their safety and efficacy have not yet been established.
Status: April 2012
Successful Products from our own Research & Development
| Product name |
First launch |
Active ingredient |
Indication |
|---|---|---|---|
| Trajenta® | 2011 | Linagliptin | Diabetes mellitus type II |
| Pradaxa® |
2010
2008
|
Dabigatran etexilate |
Stroke prevention in atrial fibrillation
Prevention of venous thromboembolic events (VTE) in adults |
|
Spiriva®
Spiriva® |
2007
|
Tiotropium |
COPD |
| Micardis® | 1998 | Telmisartan | Essential hypertension |
|
Sifrol® / Mirapex® / Mirapexin® |
2006
1997 |
Pramipexole |
Restless legs syndrome (RLS)
|
| Viramune® | 1996 | Nevirapine | HIV/AIDS |
